Alteogen

Alteogen P/B

The P/B (Price-to-Book Ratio) of Alteogen (196170.KQ) as of Nov 5, 2026 is 45.89. In the previous year, P/B (Price-to-Book Ratio) was 74.67 — a change of -38.55% (lower).

P/B

45.89

YoY

-38.55%

Last updated:

P/B (Price-to-Book Ratio) of Alteogen is 2025 45.89 . P/B (Price-to-Book Ratio) of Alteogen was 2024 74.67 . It decreases by -38.55% lower compared to the previous year.

The Alteogen P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2018
306.64 KRW
Jan 1, 2019
291.93 KRW
Jan 1, 2020
155.76 KRW
Jan 1, 2021
149.42 KRW
Jan 1, 2022
137.34 KRW
Jan 1, 2023
137.94 KRW
Jan 1, 2024
74.67 KRW
Jan 1, 2025
45.89 KRW
The Alteogen P/B history
YEARP/BYoY
45.89-38.55%
74.67-45.86%
137.94+0.44%
137.34-8.08%
149.42-4.07%
155.76-46.64%
291.93-4.80%
306.64-40.20%
512.74+13.51%
451.71-14.76%
529.95-7.07%
570.28—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alteogen Stock analysis

What does Alteogen do? Alteogen, Inc. generates revenue through its biobetter business segment, developing protein pharmaceuticals and cancer therapies, and its bio similar business segment, focusing on bio similar and animal medicines. The company sells growth hormone, herceptin, humira, antibodies, and other products primarily to healthcare providers and pharmaceutical distributors. Its biobetter segment targets oncology and protein-based treatments, while the bio similar segment serves both human and animal health markets with cost-effective alternatives to branded drugs. The firm's product portfolio includes growth hormone, herceptin, and humira, which are key revenue drivers in the biopharmaceutical sector. Herceptin and humira are well-established anticancer drugs, while growth hormone addresses endocrine disorders. The company's bio similar segment offers affordable versions of these therapies, appealing to budget-conscious healthcare systems and veterinary markets. Sales are concentrated in the human and animal medicine sectors, leveraging its dual focus on biobetter and bio similar products. Alteogen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alteogen stock

P/B (Price-to-Book Ratio) of Alteogen is 45.89 in 2025.

P/B (Price-to-Book Ratio) of Alteogen changed from 74.67 to 45.89, representing a -38.55% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Alteogen since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Alteogen with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Alteogen

All Key Metrics — Alteogen